<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14208">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02921919</url>
  </required_header>
  <id_info>
    <org_study_id>MDV3800-13</org_study_id>
    <nct_id>NCT02921919</nct_id>
  </id_info>
  <brief_title>Open-Label Extension and Safety Study of Talazoparib</brief_title>
  <official_title>A Single-Arm, Open-Label, Multicenter, Extended Treatment, Safety Study in Patients Treated With Talazoparib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medivation, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medivation, Inc.</source>
  <brief_summary>
    <textblock>
      This is a single-arm, open-label, extended treatment, safety study in patients treated with
      talazoparib in qualifying studies.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety as assessed by percentage of patients with any Adverse Event (AE), AE leading to Study Drug Discontinuation, AE leading to death, Serious Adverse Event (SAE), AE related to study drug, SAE related to study drug</measure>
    <time_frame>Anticipated in about 52 months following first patient enrolled</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Talazoparib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Talazoparib</intervention_name>
    <description>Maximum starting dose: 1mg/day or last tolerated dose in the originating protocol</description>
    <arm_group_label>Talazoparib</arm_group_label>
    <other_name>MDV3800</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eastern Cooperative Oncology Group (ECOG) performance status â‰¤ 2.

          -  Female patients of childbearing potential must have a negative pregnancy test before
             the first dose of talazoparib and must agree to use a highly effective birth control
             method from the time of the first dose of talazoparib through 45 days after the last
             dose.

          -  Male patients must use a condom when having sex with a pregnant woman or with a woman
             of childbearing potential from the time of the first dose of talazoparib through 105
             days after the last dose. Contraception should be considered for a nonpregnant female
             partner of childbearing potential.

          -  Female patients may not be breastfeeding at the first dose of talazoparib and must
             not breastfeed during study participation through 45 days after the last dose of
             talazoparib.

        Exclusion Criteria:

          -  Permanently discontinued from any Medivation sponsored study with talazoparib alone
             or in combination with another agent.

          -  Received an antineoplastic therapy or investigational agent after treatment with
             talazoparib in the originating protocol.

          -  Has a clinically significant cardiovascular, dermatologic, endocrine,
             gastrointestinal, hematologic, infectious, metabolic, neurologic, psychologic, or
             pulmonary disorder or any other condition, including excessive alcohol or drug abuse,
             or secondary malignancy, that may interfere with study participation in the opinion
             of the investigator.

          -  Diagnosis of myelodysplastic syndrome (MDS).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Medivation Clinical Operations</last_name>
    <phone>+1 (415) 543-3470</phone>
    <email>MDV3800-13MM@Medivation.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Medivation Clinical Trial Disclosure</last_name>
    <email>TrialDisclosure@Medivation.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 31, 2017</lastchanged_date>
  <firstreceived_date>September 22, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Talazoparib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
